In general, TNFR2 is a promising cellular immunotherapy target that is focused on overcoming immunosuppression, enhancing the anti-tumor response, and expanding the opportunities for personalized treatment of resistant multiple myeloma forms. Here, TNFRSF1B is linked to neoplasm.